Pfizer AG - Lorviqua 25 mg, Filmtabletten | | 66941 | | 01 | | Lorviqua 25 mg | | Filmtabletten | | L01ED05 | | Lorlatinib | | 19.02.2020 | | |
| Composition | lorlatinibum 25 mg, cellulosum microcristallinum, calcii hydrogenophosphas dihydricus, carboxymethylamylum natricum A corresp. natrium 0.315 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum 1.575 mg, macrogolum 4000, triacetinum, E 171, E 172 (nigrum), E 172 (rubrum), pro compresso obducto. | Packungsbestandteile | | Coated tablets | | | Active Agent | Dose |
---|
Lorlatinibum | 25 mg |
| BAG: Active Agent | Dose |
---|
Lorlatinibum | 25 mg |
| | Inactive agents | Dose | additional_information |
---|
(Nigrum) | | | (Rubrum) | | | Calcium Hydrogen Phosphate Dihydrate | | | Carboxymethylamylum Natricum A | | | Cellulosum Microcristallinum | | | E 171 | | color. | E 172 | | color. | Hypromellosum | | Überzug | Lactose Monohydrate | 1.575 mg | | Macrogol | 4000 | | Magnesii Stearas | | | Pro Compresso Obducto | | | Triacetinum | | |
| |
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
---|
003 | 90 | 3288.55 | 3592.90 | A | SL | Yes |
|
|